1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6F0E2696169B2269600258A150028945A
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/patient-focused-medical-affairs-excellence-building-medical-patient-teams-engaging-stakeholders-with-insights?opendocument
18
19opendocument
2044.201.72.250
21
22
23best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Medical Affairs Patient Advocacy

Patient-Focused Medical Affairs Excellence: Building Medical Patient Teams and Engaging Stakeholders with Patient Experience Insights

ID: POP-368


Features:

4 Info Graphics

24 Data Graphics

450+ Metrics

8 Narratives


Pages: 36


Published: 2023


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Medical Affairs plays an increasingly pivotal role in shaping patient-centric strategies, adapted for each franchise and therapeutic area. The demand for comprehensive data collection and dissemination to thought leaders has thrust Medical Affairs into the forefront of healthcare innovation - with patient insights on the leading edge. As patient-centric services continue to expand, staying abreast of the most effective and high-impact practices is crucial for Medical leaders.

Best Practices, LLC conducted benchmarking research to delve into the strategies employed by leading biopharmaceutical organizations in the development of Medical patient teams and their engagement with key stakeholders, driven by valuable patient experience insights. This report uncovers an array of insights, exploring high-impact activities and engagement strategies; impact of patient insights on KOL engagement; direct engagement with patients; and Medical’s utilization of patient-reported outcomes.

Industries Profiled:
Medical Device; Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Biopharmaceutical; Health Care; Clinical Research; Laboratories


Companies Profiled:
Baxter International; Bayer; Beiersdorf; DURECT Corporation; Eisai; Eurofarma; LEO Pharma; Merck; Merz Pharma; Novartis; Octave Bio; Pfizer; Sanofi; Teva Pharmaceutical Industries Ltd

Study Snapshot

Best Practices, LLC engaged 19 Medical Affairs leaders from 14 biopharma organizations in this benchmarking research.

Key topics covered in this report include:

  • Medical’s Patient Centricity Landscape
  • Internal and External Impact of Patient-Focused Medical Affairs
  • Utilizing Patient Experience Insights for External Engagement
  • Staffing, Budget, and Competencies for Patient-Focused Medical Affairs Teams

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Insight collection benefits from low-hanging fruit such as patient ad boards, direct engagement with advocacy groups, and analysis of raw data sets. Among organizations permitted to perform them, most (53%) of the benchmark class consider patient advisory boards highly effective for garnering valuable insights from patients. The next most effective tactics, used at all surveyed Medical organizations, are directly engaging patient advocacy groups (38%) and analyzing large data sets (38%). Conversely, one-on-one interviews is the most prohibited (25%) tactic.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive SummaryPg. 3-6
II.
Current Patient-Focused Medical Affairs LandscapePg. 7-12
III.
Internal and External Impact of Patient-Focused Medical AffairsPg. 13-19
IV.
Informing External Engagement with Patient Experience InsightsPg. 20-26
V.
Medical’s Key Staffing, Resources, and Competencies for Patient TeamsPg. 27-33
VI.
Participant DemographicsPg. 34-35
VII.
About Best Practices, LLCPg. 36

    List of Charts & Exhibits

    I. Executive Summary

    • Project background
    • Benchmark study partner companies
    • Key takeaways

    II. Current Patient-Focused Medical Affairs Landscape

    • Medical’s patient centricity effectiveness
    • Product focus for Medical’s patient engagement for educational and strategy purposes
    • Medical’s patient centricity hurdles
    • Medical Affairs organization’s resourcing and management related goals for patient centricity
    • Effective tactics for gathering patient insights

    III. Internal and External Impact of Patient-Focused Medical Affairs

    • High-value actions for Medical to leverage patient focus
    • Impact of patient insights on clinical trials and operations
    • Impact of patient insights on KOL & HCP education and engagement
    • Impact of patient insights on patient and advocacy support
    • Impact of patient insights to support external stakeholders such as payers, large care networks, and medical associations
    • Impact of patient insights on internal support

    IV. Informing External Engagement with Patient Experience Insights

    • Frequency of sharing patient experience data for the purpose of HCP education
    • Effectiveness of MSLs’ efforts in delivering patient experience insights to HCPs
    • Approaches for Medical Affairs professionals to engage directly with patients and patient groups
    • Frequency of interaction of patient-facing Medical Affairs leads with patients or patient representatives
    • Effectiveness of plain language summaries and related materials
    • Effectiveness of utilization of patient-reported outcomes by Medical Affairs

    V. Medical’s Key Staffing, Resources, and Competencies for Patient Teams

    • Total number of FTEs within the Medical Affairs organization that are devoted to gathering and processing patient insights or implementing patient-centric practices and programs
    • Staff background of Medical Affairs’ patient-focused teams
    • Most prevalent role for staff from each background in the Medical patient team
    • Highly effective backgrounds for patient-focused teams
    • Critical skill sets for patient-focused Medical roles
    • Total number of FTEs dedicated to utilizing patient reported outcomes (PROs) or patient reported outcome measures (PROMs)

    VI. Participant Demographics

    • Primary therapeutic area of the brands/franchises represented in the study